There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.
The researchers added that there was similarly no evidence for worse retention following a non-medical switch, and no “obvious nocebo effect.”
“Biosimilar products of biologic DMARDs entered the Swedish market in 2015,” Daniela Di Giuseppe, MSc, PhD, of the Karolinska Institutet, in Stockholm, Sweden, told Healio. “Since then, many